Carey P A, Sheridan D J, de Cordoue A, Guez D
Academic Cardiology Unit, St. Mary's Hospital Medical School, Paddington, London, United Kingdom.
Am J Cardiol. 1996 Feb 22;77(6):17b-19b. doi: 10.1016/s0002-9149(97)89234-x.
Left ventricular hypertrophy is a major risk factor for cardiovascular morbidity and mortality. Angiotensin-converting enzyme inhibitors, calcium antagonists, and beta-blockers prevent, and cause regression of, left ventricular hypertrophy after short-term therapy. The ability of diuretics to do the same is unclear. We have performed a meta-analysis of studies documenting the effect on left ventricular mass of 6 months' treatment with 2.5 mg indapamide daily. Six studies comprising 197 patients, aged 20-75 years, were included. There was an overall mean reduction in left ventricular mass index of 13.3%, which was principally due to a reduction in left ventricular wall thickness rather than internal diameter.
左心室肥厚是心血管疾病发病和死亡的主要危险因素。血管紧张素转换酶抑制剂、钙拮抗剂和β受体阻滞剂在短期治疗后可预防左心室肥厚并使其消退。利尿剂是否具有同样的作用尚不清楚。我们对记录每日服用2.5毫克吲达帕胺治疗6个月对左心室质量影响的研究进行了荟萃分析。纳入了6项研究,共197例年龄在20 - 75岁之间的患者。左心室质量指数总体平均降低了13.3%,这主要是由于左心室壁厚度的减少而非内径的减少。